



RESEARCH

Open Access

Estrogen and progesterone receptor status in breast cancer: a cross-sectional study of 450 women in Kerala, South India

Gautham Rajan^{*}, Terence B Culas^{*} and PS Jayalakshmy

Abstract

Background: Hormone receptor status is an important prognostic and therapeutic tool in breast cancer. The objectives of our study were to create a database of breast cancer patients in Central Kerala between January 2010 and December 2012 and analyze the proportions of estrogen receptor and progesterone receptor positivity in premenopausal and postmenopausal women with breast cancer.

Methods: Estrogen and progesterone receptor status were evaluated by immunohistochemistry. The chi-square test was used for statistical analysis.

Results: The median age at diagnosis was 50 years while the mean age was 51.92 (SD = 11.78). 56.1% of premenopausal and 47.4% of postmenopausal patients were found to be ER positive, while PR positivity was 47.7% and 34.7% respectively in the premenopausal and postmenopausal age groups.

Conclusions: The proportions of ER and PRnegative tumors were found to be lower than reported in earlier studies on Indian populations. Contrary to expectations, the proportions of ER and PRpositivity were found to be higher in the premenopausal age group.

Keywords: Breast cancer, estrogen receptor, progesterone receptor, premenopausal, postmenopausal, India

Background

Estrogen receptor (ER) status is an important predictive and prognostic factor in breast cancer, and determination of ER and progesterone receptor (PR) status of patients with breast carcinoma is now standard practice [1]. Though the incidence of breast cancer has been on a steady increase in Kerala [2], there have been very few studies of breast cancer in the state. This study was conducted in Government Medical College, Thrissur, a tertiary-care hospital in central Kerala. The objectives of our study were to create a database of patients in central Kerala who were detected to have breast cancer between January 2010 and December 2012 and to analyze the proportions of ER and PR positivity in premenopausal and postmenopausal women with breast carcinoma.

Methods

The study was conducted between 1 January 2010 and 31 December 2012 utilizing data available at the Department of Pathology, Government Medical College, Thrissur. Female patients with histologically proven primary breast cancer who were treated at the Department of Surgery, Government Medical College, Thrissur were made part of the study. Patients whose hormone receptor status was not determined were excluded from the study. A total of 450 patients were studied.

All hormone receptor studies were done on post-mastectomy specimens, or tissue samples obtained by core-cut biopsy prior to anterior chemotherapy. In 2010 and 2011, ER status was determined using the BioGenex monoclonal mouse IgG1 (Clone 1D5) and PR status using BioGenex monoclonal mouse IgG1 (Clone 1A6). Antigen retrieval was done using the BioGenex EZ Retriever system. In 2012, DakoEnVision + System-HRP reagent was used for identification of antigens in paraffin-embedded tissues. Pressure cooking was used for antigen retrieval.

^{*} Correspondence: gautham1988@gmail.com; tbculas@gmail.com
Government Medical College, Thrissur, Kerala, India

Monoclonal mouse IgG1 (Clone 1D5) was the antibody used to study ER status. Monoclonal mouse IgG1 (Clone PgR 636) was used to determine PR status.

The premenopausal group consisted of patients who were 50 years or younger and the postmenopausal group of patients aged 51 years and older. The Early Breast Cancer Trialists' Collaborative Group has used similar criteria to define menopause when menopausal status was not consistently defined across trials [3]. The median age at natural menopause has also been established to be 51 years [4,5]. The chi-square test was used for obtaining *P*-values and determining statistical significance. *P*-values lower than 0.05 were considered statistically significant.

Results

Out of the 450 cases of breast cancer that were studied, 237 women were premenopausal and 213 were postmenopausal. The ages of the study subjects ranged from 26 to 90 years. The median age was 50 years. In the premenopausal age group ER was positive in 133 (56.1%) patients and PR was positive in 113 (47.7%). The number of premenopausal patients who were both ER and PRpositive was 102 (43.0%). In the postmenopausal age group of 213 patients, 101 (47.4%) were ERpositive and 74 (34.7%) were PRpositive: 72 patients (33.8%) were positive for both ER and PR. Detailed analysis by age is shown in Table 1.

Discussion

It is now well-established that ERpositive tumors are associated with better overall survival compared to ERnegative tumors [6]. Determination of the hormone receptor status has been routinely performed for breast cancer patients in our institution from the year 2008. Although the American Society of Clinical Oncology (ASCO) 2010 guidelines recommend that ER and PR assays be considered positive if at least 1% of tumor nuclei are positive in the sample being tested [7], earlier studies have used a 10% cutoff. Because the definition of hormone receptor positivity varies as mentioned, results obtained using the two criteria have been summarized in Table 2.

The peak prevalence of breast cancer in central Kerala was found to be in the 41 to 50 years age group (Figure 1). The median age at diagnosis was 50 years and the mean age was 51.92 (SD 11.78). In comparison, the median age at diagnosis for cancer of the breast in the US was 61 years [8]. Because the majority of patients in India present with a higher tumor-grade and a more advanced stage at diagnosis [9,10] when compared to those in the US [8], it is likely that the actual age of onset of breast carcinoma in the Indian patient is lower by well over a decade. This younger age at onset of breast cancer can in part be explained by racial differences [10].

Data from earlier studies conducted in India reveal a higher proportion of ERnegative breast cancers when compared to the US or Western Europe; the reasons for this are several - technical failures, younger age of patients, and a higher grade or advanced stage at presentation [8-13]. In our study, the overall ERpositivity was found to be 52.0%. The average ERpositivity for white women in the US is 77% [8]. Studies done in India and in Indian emigrants have found ERpositivity in Indian women to be 34.5% [14], 35.88% [12], 37.83% [15], 38.6% [11], 49.2% [13], 50.5% [9], and 55.1% [16]. ERpositivity in premenopausal and postmenopausal women was found to be 56.1% and 47.4% respectively. This difference was not found to be statistically significant (*P*-value 0.065). Only one earlier study done in India looks at the differences in ERstatus with respect to menopausal status; ERpositivity therein was found to be 23.1% in premenopausal women and 36.6% in postmenopausal women [14].

In our series 41.5% of patients were PRpositive while 55% of white women in the US are PRpositive [8]. Other studies from India put PRpositivity at 33.3% [11], 36.4% [14], and 42% [9]. The proportions of PRpositive tumors in the premenopausal and postmenopausal age groups were found to be 47.7% and 34.7% respectively (*P*-value 0.005). Kaul *et al.* in their study conducted in the Himalayan Region of Northern India found PRpositivity to be 23.1% and 39.0% respectively in premenopausal and postmenopausal women [14].

Table 1 Age-wise analysis of study subjects

Age group, years	Cases, number	ERpositive, number (%)	PRpositive, number (%)	Both ER and PRpositive, number (%)	Both ER and PRnegative, number (%)
21 to 30	09	04 (44.4%)	05 (55.6%)	04 (44.4%)	04 (44.4%)
31 to 40	73	43 (58.9%)	37 (50.7%)	35 (47.9%)	28 (38.4%)
41 to 50	155	86 (55.4%)	71 (45.8%)	63 (40.6%)	61 (39.4%)
51 to 60	117	51 (43.6%)	40 (34.2%)	39 (33.3%)	65 (55.6%)
61 to 70	69	32 (46.4%)	23 (33.4%)	23 (33.3%)	37 (53.6%)
71 to 80	22	15 (68.2%)	10 (45.5%)	09 (40.9%)	06 (27.3%)
81 to 90	05	03 (60.0%)	01 (20.0%)	01 (20.0%)	02 (40.0%)

Table 2 Comparison of hormone receptor status based on American Society of Clinical Oncology (ASCO) 2010 and earlier criteria

Hormone receptor status	10% cutoff			1% cutoff (ASCO 2010)		
	Pre-menopausal	Post-menopausal	P-value	Pre-menopausal	Post-menopausal	P-value
ERpositivity	56.1%	47.4%	0.065	60.8%	54.5%	0.177
PRpositivity	47.4%	34.7%	0.005	58.7%	47.8%	0.022

ER, estrogen receptor; PR, progesterone, PR.

Ethnicity has been shown to be a factor in determining hormone receptor positivity. Studies in the US show that Asians have a lower ER positivity rate than non-Hispanic whites [17,18]. Our findings concur with these studies. There also appears to be geographical variations in ER positivity within India. The diet and lifestyle of our study population in Kerala, a state in the Southern tip of India with an expansive coastline, differs considerably from those of people in the North of the country. Seafood forms a prominent portion of the Kerala diet. Kerala stands first in the Human Development Index (HDI) among states in India, with an HDI of 0.790 (2011) against a national average of 0.467 (2011). Kerala also tops the country in every healthcare parameter, and awareness about breast cancer is also high among the people. These factors could explain the higher proportion of ER and PRpositive breast cancer in Kerala.

The immunohistochemistry technique used by our laboratory is standardized and is comparable with those used by other institutions in India and internationally [12-14,16]. Poor tissue handling or processing is unlikely to have altered the results obtained, as our institution has strict protocols and quality control measures.

Conclusions

Contrary to what has been reported in earlier studies, we found the proportions of ER and PRpositivity to be higher in the premenopausal age group. Though India has a higher proportion of ERnegative breast cancer than the West, the situation is not as dismal as has been previously thought. Also, women in our series tend to be younger than their Western counterparts. Better tissue handling and processing will help decrease the number of false-negatives, and will ensure that hormonal manipulation is made available to a greater number of patients with breast cancer, thus improving the outcome of the disease.

The causes leading to the loss of the ER mechanism are currently being investigated, and if proven to be an epigenetic phenomenon, as has been postulated [19], it might in the near future be possible to convert ERnegative tumors to an ERpositive phenotype, thus bringing to an end the era of non-specific chemotherapy. Moreover, in a resource-limited setting like ours, a subset of premenopausal women who are ERpositive and have completed their families, but refuse adjuvant chemotherapy therapy can be offered the alternative option of surgical oophorectomy.




Figure 1 Age distribution of study subjects. The peak prevalence of breast cancer in central Kerala was found to be in the 41 to 50 years age group.

Abbreviations

ER: estrogen receptor; PR: progesterone receptor; IgG: immunoglobulin; ASCO: American Society of Clinical Oncology; HDI: Human Development Index.

Competing interests

The authors declare that we have no competing interests, financial or otherwise.

Authors' contributions

GR participated in the study design, collected and interpreted data, and prepared the manuscript. TBC conceived of and coordinated the study, participated in the study design, and revised the manuscript. PSJ carried out the immunohistochemical studies. All authors read and approved the final manuscript.

Acknowledgements

The records maintained at the Department of Pathology, Government Medical College, Thrissur, were accessed with permission from Dr Joy Augustine, Professor and Head, Department of Pathology. MsMP Jini, Lecturer, Department of Community Medicine, Amala Institute of Medical Sciences, Thrissur, helped with the statistical analysis. Dr Lovely Jose, Assistant Professor, Department of Pathology, Government Medical College, Thrissur, shared with us her knowledge of immunohistochemistry.

Received: 16 January 2014 Accepted: 4 April 2014

Published: 24 April 2014

References

1. Rastelli F, Crispino S: **Factors predictive of response to hormone therapy in breast cancer.** *Tumori* 2008, **94**:370–383.
2. Nair MK, Sankaranarayanan R, Nair KS, Amma NS, Varghese C, Padmakumari G, Cherian T: **Overall survival from breast cancer in Kerala, India, in relation to menstrual, reproductive, and clinical factors.** *Cancer* 1993, **71**:1791–1796.
3. **Ovarian ablation in early breast cancer: overview of the randomised trials. Early breast cancer trialists' collaborative group.** *Lancet* 1996, **348**:1189–1196.
4. Gold EB, Bromberger J, Crawford S, Samuels S, Greendale GA, Harlow SD, Skurnick J: **Factors associated with age at natural menopause in a multiethnic sample of midlife women.** *Am J Epidemiol* 2001, **153**:865–874.
5. McKinlay SM, Brambilla DJ, Posner JG: **The normal menopause transition.** *Maturitas* 1992, **14**:103–115.
6. Dunnwald LK, Rossing MA, Li CI: **Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.** *Breast Cancer Res* 2007, **9**:R6.
7. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al: **ASCO-CAP guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.** *J Clin Oncol* 2010, **28**:2784–2795.
8. **SEER*Stat database.** [http://seer.cancer.gov/statfacts/html/breast.html]
9. Shet T, Agrawal A, Nadkarni M, Palkar M, Havaladar R, Parmar V, Badwe R, Chinoy RF: **Hormone receptors over the last 8 years in a cancer referral center in India: what was and what is?** *Indian J Pathol Microbiol* 2009, **52**:171–174.
10. Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS: **Spectrum of breast cancer in Asian women.** *World J Surg* 2007, **31**:1031–1040.
11. Kuraparthy S, Reddy KM, Yadagiri LA, Yutla M, Venkata PB, Kadainti SVS, Reddy RPV: **Epidemiology and patterns of care for invasive breast carcinoma at a community hospital in Southern India.** *World J Surg Oncol* 2007, **5**:56.
12. Dey S, Boffetta P, Mathews A, Brennan P, Soliman A, Mathew A: **Risk factors according to estrogen receptor status of breast cancer patients in Trivandrum, South India.** *Int J Cancer* 2009, **125**:1663–1670.
13. Manjunath S, Prabhu JS, Kaluve R, Correa M, Sridhar TS: **Estrogen receptor negative breast cancer in India: do we really have higher burden of this subtype?** *Indian J Surg Oncol* 2011, **2**:122–125.
14. Kaul R, Sharma J, Minhas SS, Mardi K: **Hormone receptor status of breast cancer in the Himalayan Region of Northern India.** *Indian J Surg* 2011, **73**:9–12.

15. Shahi KS, Bhandari G, Singh A: **Steroid receptor status and its clinicopathological correlation in postmenopausal breast cancer patients of Kumaon region of Uttarakhand.** *J Cancer Res Ther* 2011, **7**:19–22.
16. Yip CH, Pathy NB, Uiterwaal CS, Taib NA, Tan GH, Mun KS, Choo WY, Rhodes A: **Factors affecting estrogen receptor status in a multiracial Asian country: an analysis of 3557 cases.** *Breast* 2011, **20**(Suppl 2):S60–S64.
17. Chu KC, Anderson WF: **Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups.** *Breast Cancer Res Treat* 2002, **74**:199–211.
18. Li CI, Malone KE, Daling JR: **Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older.** *Cancer Epidemiol Biomarkers Prev* 2002, **11**:601–607.
19. Baum M, Sainsbury R: **Recent developments in endocrine therapy of early breast cancer.** *Recent Adv Surg* 2003, **26**:183–200.

doi:10.1186/1477-7819-12-120

Cite this article as: Rajan et al.: Estrogen and progesterone receptor status in breast cancer: a cross-sectional study of 450 women in Kerala, South India. *World Journal of Surgical Oncology* 2014 **12**:120.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

